Close Menu

The Scan

Johnson & Johnson says its candidate SARS-CoV-2 vaccine has 66 percent efficacy rate in preventing moderate-to-severe COVID-19, according to NPR.

Novavax reports its candidate SARS-CoV-2 vaccine has a high efficacy rate, though that rate dropped against the South African strain of the virus, according to the New York Times.

The Associated Press reports European Union regulators have authorized the SARS-CoV-2 vaccine from AstraZeneca and Oxford University.

In Science this week: atomic structure of the activated human minor spliceosome, and more.

Andrew Brooks Dies

Andrew Brooks, a Rutgers University professor involved in the development of saliva-based tests for SARS-CoV-2, has died at 51, People reports.

Science reports President Joe Biden has created a scientific integrity review task force.

Getting Going

The World Health Organization team exploring the origins of SARS-CoV-2 has finished its two-week quarantine in China, the Guardian says.

In Nature this week: genetic and proteomic data gives Alzheimer's disease development insights, whole-genome doubling could be targeted in cancer, and more.

The Guardian reports that Pasteur Institute researchers are halting their development of a SARS-CoV-2 vaccine following disappointing initial results.

Severity Predictor

23andMe has launched a new tool that estimates someone's risk of developing severe COVID-19 if infected, Bloomberg reports.

Shift Younger

The Wall Street Journal reports that an increased number of younger patients have been hospitalized as the new SARS-CoV-2 strain spread across the UK.

In Cell this week: proteomic patterns among COVID-19 affected tissue samples, transcriptome atlas of developing intestines, and more.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

Should Also Work

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

Million a Day

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.

US to Remain in WHO

Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.

Open Spot

Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner. 


Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.